Literature DB >> 30644767

Symptom Dimension Response in Children and Adolescents with Obsessive-Compulsive Disorder.

Joseph F McGuire1,2, Patricia Z Tan2, John Piacentini2.   

Abstract

This report examined the nature of obsessive-compulsive disorder (OCD) symptoms nominated for treatment and investigate improvement in OCD symptom dimensions. Youth with OCD (N = 71) participated in a clinical trial that compared exposure-based cognitive behavior therapy (CBT) to psychoeducation plus relaxation training (PRT). Participants completed a baseline assessment to characterize OCD severity. Next, parents and youth collaboratively developed an OCD symptom treatment hierarchy. Afterward, these symptoms were independently reassessed at each session by youth and parents. After 12 sessions, a posttreatment assessment was completed by independent evaluators. A greater incidence of baseline aggressive/checking symptoms predicted a positive CBT treatment response. For parent ratings of youth distress, CBT outperformed PRT across symptom dimensions, but hoarding symptoms exhibited a slower rate of improvement relative to other dimensions across treatments. For youth distress ratings, CBT outperformed PRT across most symptom dimensions. Although symmetry/ordering symptoms exhibited a slower rate of improvement relative to other dimensions across treatments, post hoc tests found no difference in the average distress rating for symmetry/ordering symptoms between treatment groups. Finally, across symptom dimensions, parents reported a linear reduction in youth distress, whereas youth experienced a nonlinear reduction in distress that diminished over treatment. Exposure-based CBT is beneficial for OCD symptoms and remains the principle treatment for pediatric OCD. However, as symmetry/ordering symptoms exhibited improvement from CBT and PRT, there is some shared treatment mechanisms that improves these symptoms. Finally, as youth perceive diminishing distress reduction over time, clinicians are encouraged to employ appropriate reinforcement strategies in treatment.

Entities:  

Mesh:

Year:  2019        PMID: 30644767      PMCID: PMC6754115          DOI: 10.1080/15374416.2018.1540009

Source DB:  PubMed          Journal:  J Clin Child Adolesc Psychol        ISSN: 1537-4416


  18 in total

1.  Defining treatment response and remission in obsessive-compulsive disorder: a signal detection analysis of the Children's Yale-Brown Obsessive Compulsive Scale.

Authors:  Eric A Storch; Adam B Lewin; Alessandro S De Nadai; Tanya K Murphy
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2010-06-02       Impact factor: 8.829

2.  Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial.

Authors: 
Journal:  JAMA       Date:  2004-10-27       Impact factor: 56.272

Review 3.  Assessment and management of treatment-refractory obsessive-compulsive disorder in children.

Authors:  Michael H Bloch; Eric A Storch
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2015-01-30       Impact factor: 8.829

4.  Controlled comparison of family cognitive behavioral therapy and psychoeducation/relaxation training for child obsessive-compulsive disorder.

Authors:  John Piacentini; R Lindsey Bergman; Susanna Chang; Audra Langley; Tara Peris; Jeffrey J Wood; James McCracken
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-09-22       Impact factor: 8.829

5.  Neuropsychological performance across symptom dimensions in pediatric obsessive compulsive disorder.

Authors:  Joseph F McGuire; Erika A Crawford; Jennifer M Park; Eric A Storch; Tanya K Murphy; Michael J Larson; Adam B Lewin
Journal:  Depress Anxiety       Date:  2014-02-12       Impact factor: 6.505

6.  Symptom dimensions and cognitive-behavioural therapy outcome for pediatric obsessive-compulsive disorder.

Authors:  E A Storch; L J Merlo; M J Larson; C S Bloss; G R Geffken; M L Jacob; T K Murphy; W K Goodman
Journal:  Acta Psychiatr Scand       Date:  2007-11-06       Impact factor: 6.392

7.  Concurrent validity of the anxiety disorders section of the Anxiety Disorders Interview Schedule for DSM-IV: child and parent versions.

Authors:  Jeffrey J Wood; John C Piacentini; R Lindsey Bergman; James McCracken; Velma Barrios
Journal:  J Clin Child Adolesc Psychol       Date:  2002-09

8.  Neural correlates of symptom dimensions in pediatric obsessive-compulsive disorder: a functional magnetic resonance imaging study.

Authors:  Andrew R Gilbert; Dalila Akkal; Jorge R C Almeida; David Mataix-Cols; Catherine Kalas; Bernie Devlin; Boris Birmaher; Mary L Phillips
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-09       Impact factor: 8.829

9.  Four-factor structure of obsessive-compulsive disorder symptoms in children, adolescents, and adults.

Authors:  S Evelyn Stewart; Maria C Rosario; Lee Baer; Alice S Carter; Timothy A Brown; Jeremiah M Scharf; Cornelia Illmann; James F Leckman; Denis Sukhodolsky; Lilya Katsovich; Steven Rasmussen; Wayne Goodman; Richard Delorme; Marion Leboyer; Nadia Chabane; Michael A Jenike; Daniel A Geller; David L Pauls
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-07       Impact factor: 8.829

10.  Symptom presentation and outcome of cognitive-behavioral therapy for obsessive-compulsive disorder.

Authors:  Jonathan S Abramowitz; Martin E Franklin; Stefanie A Schwartz; Jami M Furr
Journal:  J Consult Clin Psychol       Date:  2003-12
View more
  2 in total

1.  Cognitive Beliefs Across the Symptom Dimensions of Pediatric Obsessive-Compulsive Disorder: Type of Symptom Matters.

Authors:  Matti Cervin; Morgan M McNeel; Sabine Wilhelm; Joseph F McGuire; Tanya K Murphy; Brent J Small; Daniel A Geller; Eric A Storch
Journal:  Behav Ther       Date:  2021-08-20

2.  Are the symptom dimensions a predictor of short-term response to pharmacotherapy in pediatric obsessive-compulsive disorder? A retrospective cohort study.

Authors:  Anil Cifter; Ayse Burcu Erdogdu
Journal:  Indian J Psychiatry       Date:  2022-07-13       Impact factor: 2.983

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.